Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

MALVERN, Pa., Jan. 4, 2022 - Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET on the company's website, with a replay available for 30 days afterward.

Baudax Bio specializes in developing innovative products for acute care, including ANJESO, a unique 24-hour intravenous NSAID for managing moderate to severe pain, alongside a promising pipeline of neuromuscular blocking agents.

MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10 - 13, 2022.

The presentation will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:

Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:

Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

FAQ

When will Baudax Bio present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Baudax Bio will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022.

What time will the Baudax Bio presentation be available on-demand?

The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET.

How long will the Baudax Bio presentation replay be available?

The replay of the Baudax Bio presentation will be available for 30 days following the event.

What is ANJESO and how is it used?

ANJESO is the first and only 24-hour intravenous COX-2 preferential NSAID used for the management of moderate to severe pain.

What other products is Baudax Bio developing?

Baudax Bio is developing a pipeline that includes two novel neuromuscular blocking agents and a proprietary chemical reversal agent.